TARS – Tarsus Pharmaceuticals Inc
TARS — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
14.32
Margin Of Safety %
Put/Call OI Ratio
2.02
EPS Next Q Diff
-1.66
EPS Last/This Y
-0.76
EPS This/Next Y
4.84
Price
64.75
Target Price
95.14
Analyst Recom
1
Performance Q
1.3
Upside
-158.3%
Beta
0.52
Ticker: TARS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | TARS | 59.25 | 1.39 | 0.02 | 27916 |
| 2026-07-14 | TARS | 56.11 | 1.35 | 0.72 | 28249 |
| 2026-07-15 | TARS | 57.55 | 1.24 | 0.14 | 26882 |
| 2026-07-16 | TARS | 57.7 | 1.24 | 0.64 | 26888 |
| 2026-07-17 | TARS | 59.79 | 1.24 | 1.52 | 26882 |
| 2026-07-20 | TARS | 56.25 | 2.10 | 1.48 | 15567 |
| 2026-07-21 | TARS | 57.28 | 2.09 | 0.14 | 15998 |
| 2026-07-22 | TARS | 57.58 | 2.08 | 0.13 | 16008 |
| 2026-07-23 | TARS | 58.54 | 2.08 | 0.25 | 16014 |
| 2026-07-24 | TARS | 58.73 | 2.08 | 0.00 | 16029 |
| 2026-07-27 | TARS | 60.04 | 2.08 | 0.00 | 16032 |
| 2026-07-28 | TARS | 58.9 | 2.08 | 0.00 | 16017 |
| 2026-07-29 | TARS | 58.44 | 2.08 | 999.99 | 16024 |
| 2026-07-30 | TARS | 59.51 | 2.08 | 0.00 | 16023 |
| 2026-07-31 | TARS | 58.99 | 2.08 | 999.99 | 16023 |
| 2026-08-03 | TARS | 61.24 | 2.08 | 0.00 | 16023 |
| 2026-08-04 | TARS | 61.04 | 2.08 | 0.06 | 16025 |
| 2026-08-05 | TARS | 61.31 | 2.02 | 0.10 | 16194 |
| 2026-08-07 | TARS | 64.8 | 2.02 | 0.00 | 16266 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | TARS | 59.26 | 47.6 | - | -0.59 |
| 2026-07-14 | TARS | 56.19 | 50.3 | - | -0.59 |
| 2026-07-15 | TARS | 57.52 | 50.8 | - | -0.59 |
| 2026-07-16 | TARS | 57.69 | 50.8 | - | -1.04 |
| 2026-07-17 | TARS | 59.80 | 64.6 | - | -2.25 |
| 2026-07-20 | TARS | 56.25 | 64.6 | - | -2.25 |
| 2026-07-21 | TARS | 57.29 | 64.6 | - | -2.25 |
| 2026-07-22 | TARS | 57.53 | 63.9 | - | -2.25 |
| 2026-07-23 | TARS | 58.50 | 63.9 | - | -2.25 |
| 2026-07-24 | TARS | 58.62 | 63.5 | - | -2.25 |
| 2026-07-27 | TARS | 60.15 | 63.5 | - | -2.25 |
| 2026-07-28 | TARS | 58.96 | 63.5 | - | -2.25 |
| 2026-07-29 | TARS | 58.50 | 63.5 | - | -2.25 |
| 2026-07-30 | TARS | 59.47 | 63.5 | - | -2.25 |
| 2026-07-31 | TARS | 58.98 | 63.5 | - | -2.25 |
| 2026-08-03 | TARS | 61.22 | 63.5 | - | -2.25 |
| 2026-08-04 | TARS | 61.22 | 63.5 | - | -2.25 |
| 2026-08-05 | TARS | 61.22 | 59.2 | - | -2.35 |
| 2026-08-06 | TARS | 65.42 | 59.2 | - | -2.35 |
| 2026-08-07 | TARS | 64.75 | 59.2 | - | -2.35 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | TARS | -5.55 | 0.03 | 14.58 |
| 2026-07-14 | TARS | -5.55 | 0.03 | 14.58 |
| 2026-07-15 | TARS | -5.55 | 0.03 | 14.58 |
| 2026-07-16 | TARS | -5.55 | 0.03 | 14.58 |
| 2026-07-17 | TARS | -5.55 | 0.03 | 14.58 |
| 2026-07-20 | TARS | -5.55 | 1.00 | 14.58 |
| 2026-07-21 | TARS | -5.55 | 1.00 | 14.58 |
| 2026-07-22 | TARS | -5.55 | 1.00 | 14.58 |
| 2026-07-23 | TARS | -5.55 | 1.00 | 14.58 |
| 2026-07-24 | TARS | -5.55 | 1.00 | 14.58 |
| 2026-07-27 | TARS | -5.55 | 1.00 | 14.32 |
| 2026-07-28 | TARS | -5.55 | 1.00 | 14.32 |
| 2026-07-29 | TARS | -5.55 | 1.00 | 14.32 |
| 2026-07-30 | TARS | -5.55 | 1.00 | 14.32 |
| 2026-07-31 | TARS | -5.55 | 1.00 | 14.32 |
| 2026-08-03 | TARS | -5.55 | 0.94 | 14.32 |
| 2026-08-04 | TARS | -5.55 | 0.94 | 14.32 |
| 2026-08-05 | TARS | -5.55 | 0.94 | 14.32 |
| 2026-08-06 | TARS | -5.55 | 0.94 | 14.32 |
| 2026-08-07 | TARS | -5.55 | 0.94 | 14.32 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.16
Avg. EPS Est. Current Quarter
-0.2
Avg. EPS Est. Next Quarter
-1.82
Insider Transactions
-5.55
Institutional Transactions
0.94
Beta
0.52
Average Sales Estimate Current Quarter
167
Average Sales Estimate Next Quarter
181
Fair Value
Quality Score
54
Growth Score
53
Sentiment Score
59
Actual DrawDown %
24
Max Drawdown 5-Year %
-62.7
Target Price
95.14
P/E
Forward P/E
29.14
PEG
P/S
4.6
P/B
8.09
P/Free Cash Flow
49.78
EPS
-1.08
Average EPS Est. Cur. Y
-2.35
EPS Next Y. (Est.)
2.48
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-7.67
Relative Volume
1
Return on Equity vs Sector %
-41.2
Return on Equity vs Industry %
-25.1
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-1.76
EBIT Estimation
◆
TARS
Healthcare
$64.79
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
59.9
Range 1M
60.1%
Sup Dist
7.6%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-24.8%
EPS NY
212.1%
52W%
44.1%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+37.7% upside
Upside
+37.7%
Quality
54
TARS — P/E HistoricalBiotechnology
Tarsus Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 370
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
TARS
Latest News
—
Caricamento notizie per TARS…
stock quote shares TARS – Tarsus Pharmaceuticals Inc Stock Price stock today
news today TARS – Tarsus Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch TARS – Tarsus Pharmaceuticals Inc yahoo finance google finance
stock history TARS – Tarsus Pharmaceuticals Inc invest stock market
stock prices TARS premarket after hours
ticker TARS fair value insiders trading